EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients

Helena A Peters iD, Daniel Weiss, Matthias Boschheidgen, Eduards Mamlins, Frederik L Giesel, Georg Fluegen, Julian Kirchner, Gerald Antoch, Kai Jannusch

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Helena A Peters und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Düsseldorf, Düs…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Lung Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to evaluate the prognostic potential of pre-therapeutic [ 18 F]FDG-PET/CT variables regarding prediction of progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.

Method

NSCLC-patients who underwent pre-therapeutic [ 18 F]FDG-PET/CT were retrospectively analyzed. The following imaging features were collected from the primary tumor: tumor size, tumor density, central necrosis, spicules and SUV max . For standardization, an indexSUV max was calculated (SUV max primary tumor/SUV max liver). Descriptive statistics and correlations of survival time analyses for PFS and OS were calculated using the Kaplan-Meier method and Cox regression including a hazard ratio (HR). A value of p < 0.05 was set as statistically significant. The 95%-confidence intervals (CI) were calculated. The median follow-up time was 63 (IQR 27–106) months.

Results

This study included a total of 82 patients (25 women, 57 men; mean age: 66 ± 9 years). IndexSUV max (PFS: HR = 1.0, CI: 1.0–1.1, p = 0.49; OS: HR = 1.0, CI: 0.9–1.2, p = 0.41), tumor size (PFS: HR = 1.0, CI: 0.9–1.0, p = 0.08; OS: HR = 1.0, CI: 0.9–1.0, p = 0.07), tumor density (PFS: HR = 0.9, CI: 0.6–1.4, p = 0.73; OS: HR = 0.3; CI: 0.1–1.1; p = 0.07), central necrosis (PFS: HR = 1.0, CI: 0.6–1.8, p = 0.98; OS: HR = 0.6, CI: 0.2–1.9, p = 0.40) and spicules (PFS: HR = 1.0, CI: 0.6–1.9, p = 0.91; OS: HR = 1.3, CI: 0.4–3.7, p = 0.65) did not significantly affect PFS and OS in the study population. An optimal threshold value for the indexSUV max was determined by ROC analysis and Youden’s index. There was no significant difference in PFS with an indexSUV max -threshold of 3.8 (13 vs. 27 months; p = 0.45) and in OS with an indexSUV max -threshold of 4.0 (113 vs. 106 months; p = 0.40).

Conclusions

SUV max and morphologic parameters from pre-therapeutic [ 18 F]FDG-PET/CT were not able to predict PFS and OS in NSCLC-patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyLung NeoplasmsProgression-Free SurvivalHumansMaleFemaleAgedMiddle AgedPrognosisRetrospective StudiesRadiopharmaceuticalsKaplan-Meier Estimate

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Department of Surgery, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Düsseldorf, Germany.

ORCID-Profile: Helena A Peters

Zitieren

APA

Peters, H. A., Weiss, D., Boschheidgen, M., Mamlins, E., Giesel, F. L., Fluegen, G., Kirchner, J., Antoch, G., & Jannusch, K. (2024). Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0307998

Vancouver

Peters HA, Weiss D, Boschheidgen M, Mamlins E, Giesel FL, Fluegen G, et al. Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients. PLOS ONE. 2024. doi:10.1371/journal.pone.0307998

BibTeX
@article{Peters2024,
  author = {Peters, Helena A and Weiss, Daniel and Boschheidgen, Matthias and Mamlins, Eduards and Giesel, Frederik L and Fluegen, Georg and Kirchner, Julian and Antoch, Gerald and Jannusch, Kai},
  title = {Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307998}
}
Kostenlos starten →